All Articles
Pharma Readiness for Diagnostic Integration 2017

Pharma Readiness for Diagnostic Integration 2017

14 March, 2017

This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precision medicine beyond molecular testing and makes considered predictions for the developing industry.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny